Better Health for All

Cumberland Pharmaceuticals Inc. focuses on acquiring, developing, and commercializing branded prescription products, with its entire business devoted to health improvement. Its pipeline includes drug candidates for Duchenne muscular dystrophy (DMD) cardiomyopathy, idiopathic pulmonary fibrosis (IPF), and systemic sclerosis (SSc), all serious conditions.

Preclinical studies suggest these candidates may improve cardiac function, reduce fibrosis, and increase survival in animal models. The company's existing product portfolio also consists of prescription medications intended for health benefits, with no evidence of products having negative health consequences. The company has received Orphan Drug Designation and Rare Pediatric Disease Designation for ifetroban for DMD cardiomyopathy. However, the company has faced regulatory action, including a Warning Letter from the FDA in 2022 regarding manufacturing deficiencies for certain products, indicating a notable safety incident. The company also holds patents on its products, including ifetroban, and there is no evidence of patent flexibility or access programs for low-income countries.

Fair Money & Economic Opportunity

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on acquiring, developing, and commercializing branded prescription products.

The company's core business activities do not involve lending, insuring, moving, or storing money, nor does it offer consumer financial products or services. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives (financial), data accessibility (financial), fair lending compliance, wealth building outcome, profit reinvestment (community finance), financial literacy initiatives, debt burden ratio, geographic inclusion (financial access points), and product simplicity (financial products), are not applicable to its operations. While the company offers patient assistance programs for affordable medication and serves underserved patient populations, these initiatives do not fall under the scope of financial services as defined by the 'Fair Money & Economic Opportunity' value.

Fair Pay & Worker Respect

No quantitative data relevant to the Fair Pay & Worker Respect metrics was found in the provided articles. The articles primarily consist of employee reviews and general ratings (e.g., 3.3 out of 5 stars on Indeed, 2.3 out of 5 stars on Glassdoor for overall employee rating), which do not provide specific, measurable data points for KPIs such as living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

One article explicitly listed all these key metrics as missing.

Honest & Fair Business

The provided articles indicate that Cumberland Pharmaceuticals has a 'Standards of Business Conduct and Ethics' and adheres to 'PhRMA Code Compliance'.

However, there is no specific, concrete data available in the articles to score any of the KPIs for Honest & Fair Business, such as regulatory fines, transparency index, whistleblower policy, financial restatements, audit coverage, ESG controversy index, complaint resolution time, board conflict-free percentage, anti-corruption policy strength, or third-party verification of ethical claims. Therefore, no KPIs can be scored based on the provided evidence.

Kind to Animals

The company uses animals for drug testing and clinical trials, as evidenced by a product profile stating that a drug "may cause fetal harm, based on animal data."

There is no information provided regarding any formal animal testing policy, reduction commitments, or ethical oversight. The company's business model involves drug development, which inherently relies on animal testing for safety and efficacy, often due to legal mandates.

No War, No Weapons

The provided articles, including Cumberland Pharmaceuticals' inaugural ESG report for 2019, explicitly state that no quantitative data related to the company's involvement in war, weapons, or peacebuilding initiatives is available.

Therefore, no specific evidence exists to score any of the 'No War, No Weapons' KPIs.

Planet-Friendly Business

Cumberland Pharmaceuticals reported a current carbon footprint of 22,500 metric tons CO2 equivalent annually, with 14,625 metric tons from manufacturing facilities and 7,875 metric tons from transportation and distribution.

The company has a carbon emissions reduction target of 15% compared to a 2022 baseline, but no evidence of achieved annual reduction was provided. The company's waste recycling rate is 42%, with a target to reach 65% by 2026. There were no environmental compliance violations reported in 2023, and the company underwent 2 routine FDA inspections in 2023. The company has not declared a net-zero target year and has not conducted climate scenario analysis. In 2024, Cumberland Pharmaceuticals invested $1.2 million in environmental sustainability initiatives and allocated $3.5 million to green chemistry research.

Safe & Smart Tech

The company experienced a publicly reported ransomware attack, which resulted in the unauthorized exfiltration of financial, personal, client personal, and accounting data.

This constitutes an incident of unauthorized data use.

Zero Waste & Sustainable Products

In 2024, the company safely disposed of nearly 12,480 pounds of damaged or expired products.

In 2023, it safely disposed of nearly 6,000 pounds of damaged or expired products. This demonstrates compliant hazardous waste handling, aligning with industry standard practices.